Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 2;15(2):e70107.
doi: 10.1002/pul2.70107. eCollection 2025 Apr.

Lung Transplant Outcomes in Patients With Preoperative Catheterization Indicating Group 2 Pulmonary Hypertension

Víctor M Mora-Cuesta  1   2   3 , Amaya Martínez-Meñaca  1   2   3 , David Iturbe-Fernández  1   2   3 , Sandra Tello-Mena  1   2 , Sheila Izquierdo-Cuervo  1   2 , Tamara García-Camarero  4 , Aritz Gil-Ongay  4 , Pilar Alonso-Lecue  3 , José M Cifrián-Martínez  1   2   3 , Diego Agustín Rodríguez-Chiaradia  5   6 , Pilar Escribano-Subías  2   7   8   9 , Esther Barreiro  5   10   11
Affiliations

Lung Transplant Outcomes in Patients With Preoperative Catheterization Indicating Group 2 Pulmonary Hypertension

Víctor M Mora-Cuesta et al. Pulm Circ. .

Abstract

Lung transplantation (LT) is a well-established therapeutic option for patients with advanced chronic respiratory diseases. This study aims to assess the prevalence and clinical impact of Group 2 pulmonary hypertension (PHg2) in LT recipients, comparing it with Group 3 pulmonary hypertension (PHg3). This retrospective cohort study analyzed LT recipients from 2015 to 2024 at a single center. Patients were categorized into three groups based on hemodynamic measurements: no PH, PHg2, and PHg3. Hemodynamic data were acquired via right heart catheterization. Perioperative complications, including primary graft dysfunction (PGD), and long-term survival were compared across the groups. Of the 412 LT recipients, 40 (10.9%) were diagnosed with PHg2, while 62.5% had PHg3. Statistical analysis revealed no significant differences in perioperative outcomes, including the incidence of PGD, between patients with PHg2 and those with PHg3. Additionally, there were no differences in long-term survival between the groups. Within the PHg2 subgroup, patients with isolated PHg2 and those with combined PHg2 exhibited similar post-transplant outcomes. PHg2 is identified in a notable fraction of LT recipients, yet it does not appear to adversely affect perioperative complications or long-term survival when compared to PHg3 or patients without PH. These findings suggest that PHg2, despite its prevalence, does not significantly alter transplant outcomes. Future multicenter studies are needed to further explore the impact of subtle left ventricular dysfunction on LT results.

Keywords: lung transplantation; primary graft dysfunction; pulmonary hypertension.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart of the patients included in the study. Abbreviations: PAH = pulmonary arterial hypertension; PH = pulmonary hypertension; PHg2 = pulmonary hypertension group 2; PHg3 = pulmonary hypertension group 3; PWP = pulmonary wedge pressure.
Figure 2
Figure 2
(A) Survival of the different study groups after transplantation. (B) Survival of the different PHg2 groups after transplantation.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Weill D., Benden C., Corris P. A., et al., “A Consensus Document for the Selection of Lung Transplant Candidates: 2014—An Update From the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation,” Journal of Heart and Lung Transplantation 34, no. 1 (January 2015): 1–15, 10.1016/j.healun.2014.06.014. - DOI - PubMed
    1. Leard L. E., Holm A. M., Valapour M., et al., “Consensus Document for the Selection of Lung Transplant Candidates: An Update From the International Society for Heart and Lung Transplantation,” Journal of Heart and Lung Transplantation 40, no. 11 (November 2021): 1349–1379, 10.1016/j.healun.2021.07.005. - DOI - PMC - PubMed
    1. Mora‐Cuesta V. M., Martínez‐Meñaca A., Iturbe‐Fernández D., et al., “Impact of the New Definition of Pulmonary Hypertension on the Prevalence of Primary Graft Dysfunction in Lung Transplant Recipients,” Heart, Lung and Circulation 33, no. 4 (April 2024): 524–532, 10.1016/j.hlc.2023.12.019. - DOI - PubMed
    1. Cottini S. R., Brandi G., Pagnamenta A., et al., “Pulmonary Hypertension Is Not a Risk Factor for Grade 3 Primary Graft Dysfunction After Lung Transplantation,” Clinical Transplantation 32, no. 5 (May 2018): e13251, 10.1111/ctr.13251. - DOI - PubMed
    1. Diamond J. M., Arcasoy S., Kennedy C. C., et al., “Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, Part II: Epidemiology, Risk Factors, and Outcomes—A 2016 Consensus Group Statement of the International Society for Heart and Lung Transplantation,” Journal of Heart and Lung Transplantation 36, no. 10 (October 2017): 1104–1113, 10.1016/j.healun.2017.07.020. - DOI - PubMed

LinkOut - more resources